Deliver a robust portfolio of early hits and lead series to enable drug discovery for Chagas disease
current phase of drug development
updated 15 Feb 2023
To identify new hit series that could be progressed and become new drug candidates for Chagas disease, DNDi tests chemical compounds for in vitro activity against T. cruzi. Collections of natural and synthetic compounds are typically accessed from partners and commercial suppliers, and high-throughput screening is conducted in collaboration with University of Dundee and Institut Pasteur Korea.
In 2015, to complement bilateral collaborations for screening and lead optimization, DNDi launched the NTD Drug Discovery Booster with several major pharmaceutical companies. The NTD Drug Discovery Booster continued until 2019, when screening activities were placed on hold to focus efforts on transitioning existing hit series into lead optimization projects.
Get our latest news, personal stories, research articles, and job opportunities.